- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02567383
Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer
July 27, 2020 updated by: Shin Kong Wu Ho-Su Memorial Hospital
A Phase II Clinical Trial Evaluating the Safety and Efficacy of Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer
Clinical experience of with hyperthermia combined with radiotherapy and chemotherapy for recurrent head and neck cancer is limited.
The primary goals of hyperthermia combined with CCRT on recurrent head and neck cancer are tumor response rate, while secondary goals are rates of acute and late adverse effects, local control rate, distant metastasis rate, progression-free rate and overall survival rate.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Patients will be treated with radiotherapy with 50Gy/22fx/6 weeks, plus hyperthermia for 40 minutes within 2hr after irradiation, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, once a week since the 1st week of radiation for a total of 6 times.
The regimen of concurrent chemotherapy will be cisplatin 20mg/m2 and taxotere 10-12mg/m2 per week for 6 weekly cycles on the day before radiotherapy and hyperthermia treatment.
The two chemotherapy agents will be given in only one day every week, according to the weekly dose.
According to Gehan two-stage design, provided the estimated tumor response rate using this regimen is about 40% and objective tumor response is observed in ≥1 of the first 6 patients enrolled, α<0.05 will be achieved indicating a preliminary efficacy.
Then the Gehan second stage will be started.
With a set of 5% precision and an assumption of 10% dropout rate, 39 additional patients will be enrolled in the Gehan second stage depending on the actual number with tumor response in the Gehan first stage (totaling 45 patients when counting the first 6 in the Gehan first stage).
The tumor response, adverse effects and various survival curves will be analyzed.
Study Type
Interventional
Enrollment (Anticipated)
45
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kwan-Hwa Chi, M.D.
- Phone Number: 2274 886-2-28332211
- Email: M006565@ms.skh.org.tw
Study Contact Backup
- Name: Kai-Lin Yang, M.D.
- Phone Number: 2275 886-2-28332211
- Email: M011360@ms.skh.org.tw
Study Locations
-
-
-
Taipei, Taiwan
- Recruiting
- Shin Kong Wu Ho-Su Memorial Hospital
-
Contact:
- Kwan-Hwa Chi, M.D.
- Phone Number: 2274 886-2-28332211
- Email: M006565@ms.skh.org.tw
-
Contact:
- Kai-Lin Yang, M.D.
- Phone Number: 2275 886-2-28332211
- Email: M011360@ms.skh.org.tw
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age of 20-85 years, with ECOG performance 0-2.
- Treatment failure head and neck cancer, with histologically or clinically confirmed recurrence or progression after previous treatment of radiotherapy with combinations.
- Complete surgical excision is NOT feasible as salvage treatment for the recurrent or progressive tumor(s), or the patient does NOT agree to receive the surgical procedure.
- Salvage radiotherapy is possible, and a total dose of 50Gy/22fx is considered tolerable.
- Measurable lesions by image examinations or endoscopy within 2 months.
- The distribution of the lesions of interest does NOT exceed 20cm range.
- The patient can tolerate implementation of cisplatin and taxotere weekly therapy, with respect to hematopoietic status, renal function, liver function, allergy and other potential adverse effects.
- There is NO other effective treatment option according to the evaluation of physicians.
Exclusion Criteria:
- Re-irradiation of 50Gy/22fx is considered NOT tolerable.
- Future tumor response to treatment in this study is NOT possibly evaluated using image examinations or endoscopy.
- The patient is participating in other clinical trials.
- Future regular clinical follow-up is NOT possible.
- The patient has large-area metallic implants or tattoos including much metal powder within hyperthermia field (not including metallic hemoclips with small area and few numbers).
- The patient has pacemakers, electrocardiograph, defibrillator implanted, or adhesive skin patches including conductive metal.
- The patients with ocular or cerebral disorders within hyperthermia field.
- Tumor invasion of great or large vessels exists, or patients with any existing complications that may pose risks to hyperthermia treatment.
- Patients who have difficulty with communication.
- Other patients who are considered to have a contraindication to hyperthermia treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hyperthermia
Hyperthermia; Thermotron RF-8, radiation, Cisplatin and Taxotere
|
5-Gy once a week for a subtotal of 10Gy/2fx a week to gross tumors, followed by 40Gy/20fx/4 weeks, total 50Gy/22fx/5weeks
40 minutes within 2hr after irradiation
20mg/m2 per week for 6 weekly cycles before radiotherapy
10-12mg/m2 per week for 6 weekly cycles before radiotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor response rate
Time Frame: 12 Weeks
|
To estimate the tumor response rate (complete response + partial response; CR + PR; according to RECIST criteria version 1.1) using hyperthermia combined with CCRT for recurrent head and neck cancer.
|
12 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Within 3 months
|
To estimate rates of each grade adverse events (CTCAE, version 4.0) which is possibly, probably, or definitely related to treatment and which occurs within 3 months from the start of radiation combined with hyperthermia and chemotherapy.
|
Within 3 months
|
Late adverse events
Time Frame: After 3 months
|
To estimate rates of late adverse events (3 months from start of radiation combined with hyperthermia and chemotherapy)
|
After 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Anticipated)
March 1, 2021
Study Completion (Anticipated)
March 1, 2021
Study Registration Dates
First Submitted
October 1, 2015
First Submitted That Met QC Criteria
October 2, 2015
First Posted (Estimate)
October 5, 2015
Study Record Updates
Last Update Posted (Actual)
July 28, 2020
Last Update Submitted That Met QC Criteria
July 27, 2020
Last Verified
July 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Neoplasms by Site
- Wounds and Injuries
- Disease Attributes
- Body Temperature Changes
- Heat Stress Disorders
- Head and Neck Neoplasms
- Recurrence
- Hyperthermia
- Fever
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
- Cisplatin
Other Study ID Numbers
- 20150205D
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Head and Neck Cancer
-
UNICANCERCompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerFrance
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerChina
-
Merck Sharp & Dohme LLCCompletedRecurrent Head and Neck Cancer | Metastatic Head and Neck Cancer
-
Dana-Farber Cancer InstituteActive, not recruitingRecurrent Head and Neck Carcinoma | Head and Neck Cancer Metastatic | Head or Neck CancerUnited States
-
Royal Marsden NHS Foundation TrustRecruitingRecurrent Head and Neck CancerUnited Kingdom
-
Rakuten Medical, Inc.CompletedRecurrent Head and Neck CancerUnited States
-
University of Colorado, DenverCompletedRecurrent Head and Neck CancerUnited States
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
AmgenCompletedRecurrent and/or Metastatic Head and Neck Cancer
Clinical Trials on Radiation
-
Canadian Cancer Trials GroupAlliance for Clinical Trials in Oncology; NRG Oncology; Eastern Cooperative Oncology... and other collaboratorsRecruitingBreast CancerUnited States, Canada
-
Cancer Institute and Hospital, Chinese Academy...Terminated
-
Massachusetts General HospitalCompletedMesenchymal TumorUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma | Ann... and other conditionsUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingStage III Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8United States
-
University of ChicagoRecruitingLymphoma | Hodgkin Lymphoma | Non-hodgkin LymphomaUnited States
-
University of Texas Southwestern Medical CenterCompletedNon-small Cell Lung CancerUnited States
-
Maastricht Radiation OncologyThe Netherlands Cancer Institute; Diakonessenhuis, UtrechtCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Extranodal Marginal Zone LymphomaUnited States